西妥昔单抗联合化疗治疗转移性结直肠癌的临床观察

A Clinical Observation of Cetuximab Combined with Chemotherapy for Metastatic Colorectal Cancer Patients

目的:观察西妥昔单抗联合FOLFIRI或FOLFOX方案治疗转移性结直肠癌的近期疗效及毒副反应。方法:2006年11月至2009年1月,我院收治的12例转移性结直肠癌患者,接受西妥昔单抗联合化疗治疗,西妥昔单抗首次给予负荷剂量400mg/m^2,而后每周维持量为250mg/m^2。有7例联合FOLFIRI方案,4例联合FOLFOX方案,1例联合奥沙利铂+放疗。分别按照RECIST标准和NCI-CTC 3.0评价疗效和毒性。结果:全组12例均可评价疗效,.PR 7例,SD 3例,PD 2例,总有效率58.3%,疾病控制率83.3%。疾病进展时间(TTP)1.5个月～15个月。主要毒副反应为痤疮样皮疹和腹泻。结论:西妥昔单抗联合FOLFIRI或FOLFOX方案治疗转移性结直肠癌安全有效,除痤疮样皮疹外,毒副作用无明显增加。

Objective： To observe the efficacy and toxicity of cetuximab plus chemotherapy containing irinotecan or oxaliplatin in the treatment of metastatic colorectal cancer. Methods： From November 2006 to January 2009,12 patients with metastatic colorectal cancer histologically confirmed were treated with cetuximab combined with chemotherapy containing irinotecan or oxaliplatin regimen. Cetuximab was given at an initial dose of 400mg/m^2, followed by weekly infusions of 250mg/m^2, including 7 patients combined with FOLFIRI regimen,4 patients combined with FOLFOX regimen and 1 patient combined with oxaliplatin regimen and radiotherapy. The efficacy and toxicity were evaluated according to RECIST and NCI-CTC 3.0 criteria. Results： The effects could be observed in 12 patients. 7 patients got PR, 3 patients SD and 2 patients PD, with the response rate of 58.3% and the disease control-rate of 83.3 %. The time to progression （TIP） was 1.5 -15 months. The major toxicities were none-like rash and diarrhea. Conclusion： Cetuximab combined with the chemotherapy containing irlnotecan or oxaliplatin has clinical efficacy in patients with metastatic colorectal cancer. No more toxicities, except rash, are observed in the patients receiving cetuximab combined with chemotherapy than chemotherapy alone.